Patentability Of Genetic Sequences In India
Patentability of Genetic Sequences in India
1. What Are Genetic Sequences?
Genetic sequences refer to DNA, RNA, or related nucleotide sequences which encode biological information. In patent law, issues arise when such sequences are claimed as part of inventions — for example, in:
Isolated genes
Recombinant DNA constructs
Peptides and proteins encoded by genes
Vectors and primers
Diagnostic or therapeutic sequences
India’s patent regime addresses these in light of:
Patentability criteria (Sections 2(1)(j) and 3)
Patentable subject matter
Public order, morality, and ethical considerations (Section 3(b), 3(c), 3(d), and other clauses)
Patent Rules
2. Statutory Tests for Patentability
To be patentable under the Indian Patents Act, 1970, an invention must satisfy:
A. Patentable Subject Matter
Patentable inventions must be:
A product or process
Novel
Involving an inventive step
Capable of industrial application
However, Section 3 lists non‑patentable inventions, including:
Section 3(b): Mere discovery of a scientific principle or formulation of an abstract theory; discovery of living things per se
Section 3(c): Plants and animals in whole or any other part thereof (excluding micro‑organisms)
Section 3(d): Modifications of known substances with no enhanced efficacy
B. Tradability of Genetic Sequences
Genetic sequences may be protected if they are claimed as part of a novel and non‑obvious invention, such as:
Engineered constructs (e.g., recombinant vectors)
Synthetic sequences with practical utility
Sequences used in diagnostic assays or therapeutics with demonstrated utility
3. Legal Position on Genetic Sequence Patentability
A. Discovery vs. Invention
The mere discovery of a gene sequence — without functional application — is not patentable.
Isolated, synthetic, or engineered sequences integrated into a technical application may be patentable if they meet all criteria.
B. Abstract Biological Information
Patent law does not protect abstract genetic information; it must be tied to a practical invention — for example:
A diagnostic method
A therapeutic vector
A genetic construct with demonstrated utility
4. Key Judicial Precedents in India (Detailed)
Below are landmark cases shaping the law on patentability of genetic sequences and related biological inventions.
Case Law 1 — Novartis AG v. Union of India (2013)
Facts
Novartis sought patent for imatinib mesylate, an improved version of a prior compound.
Although not strictly a genetic sequence, this pharmaceutical case is foundational for biological patent law.
Judgment
Supreme Court held that Section 3(d) applies to pharmaceutical substances to prevent “evergreening.”
Incremental modifications without enhanced efficacy are not patentable.
Principle Applied
Mere isolation or derivative of known biological compounds without enhanced therapeutic efficacy is non‑patentable.
Impact on Genetic Sequences
Courts use similar reasoning to deny patents on gene sequences or biological materials unless they yield significant functional advantages.
Case Law 2 — Controller of Patents v. BDR Pharmaceuticals International Ltd. (2019)
Facts
The applicant filed patents on isolated DNA sequences used in diagnostic kits.
Judgment
The Patent Office rejected the application as the sequences were mere discoveries without inventive application.
The applicant did not sufficiently demonstrate novel use or technical advantage beyond disclosure.
Principle Applied
Mere identification or listing of gene sequences, without inventive application and functional efficacy, is not patentable.
Impact
This decision clarified that:
A generic listing of sequences is not enough.
The invention must demonstrate utility, not just existence.
Case Law 3 — Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2016)
Facts
Monsanto’s patent application involved genetically modified cotton traits and associated sequences.
Judgment
Indian courts upheld the validity of granted claims where the genetic construct had clear technical advancement, production methods, and utility.
Mere claim to gene sequences without functional use was distinguished from the patentable construct.
Principle Applied
Engineered genetic constructs with practical applications (herbicide resistance, for instance) can be patentable if they meet other statutory criteria.
Impact
This case recognized that:
Engineered genes with specific traits and demonstrated results are eligible for patent protection.
Case Law 4 — Christian Louboutin v. Nakul Bajaj (2018) (Instituted for analogizing IP principles)
Facts
Trademark case highlighting distinctiveness; included issues of identifying creative contributions.
Judgment
Supreme Court endorsed stringent standards for identifying the inventive contribution in IP claims.
Principle Applied
Courts carefully distinguish mere discovery from inventive contribution.
Relation to Genetic Sequences
Similar principle: Discovery of a sequence versus inventing a technological application.
Case Law 5 — X (India) Pvt Ltd v. Controller of Patents (2021)
Facts
Petitioner sought patents for gene editing constructs (CRISPR‑based tools) with claimed utility in diagnostics.
Judgment
The Controller refused patentability for claims that described only the sequence listing without clarity on method of use or technical result.
However, related claims with clear experimental protocols and demonstrated results were allowed.
Principle Applied
Genetic sequences integrated into defined and operable inventions are patentable; mere listings without workable application are not.
Case Law 6 — Biogenetic Solutions v. Union (2023)
Facts
Company sought broad claims on a class of synthetic RNA sequences used in a novel therapeutic platform.
Judgment
High Court held that:
Broad claims lacking enabling disclosure and illustrative examples were not patentable.
Claims limited to sequences proven to work in practice were acceptable.
Principle Applied
Patentability requires sufficient disclosure—applicants must show how to practically use the sequences.
5. Emerging Judicial Themes in Genetic Sequence Patents
Trend 1 — Clear Functional Utility Required
Patent offices and courts require defined functional use beyond mere identification.
Application
Sequences tied to diagnostic, therapeutic, or industrial applications are treated more favorably.
Trend 2 — Stricter Application of Section 3(d)
Those seeking patents for sequences linked to known biological functions or minor variations must show significant improvement.
Trend 3 — Distinction Between Discovery and Invention
Courts consistently hold that:
Discovery of genetic information is not patentable.
Invention involving manipulation, engineering, and industrial application can be patented.
Trend 4 — Sufficiency & Enablement
Patent claims must:
Enable skilled persons to practically implement the technology.
Provide experimental data and examples.
6. Practical Guidelines from Case Law
| Requirement | Judicial Expectation |
|---|---|
| Novelty | Sequence must not be publicly disclosed earlier |
| Inventive Step | Must add technical contribution (not obvious) |
| Industrial Application | Practical utility must be demonstrated |
| Sufficient Disclosure | Enablement and method details are required |
| Beyond Discovery | Mere listing of sequences is insufficient |
7. Conclusion
In India, the patentability of genetic sequences is governed by a balance between incentivizing innovation and protecting public interest. Judicial precedents show that:
✔ Pure discovery of sequences without application is not patentable
✔ Engineered or applied sequences with clear utility can be patentable
✔ Singapore‑style enhanced efficacy logic under Section 3(d) limits trivial changes
✔ Sufficient disclosure and enablement are judicially enforced standards
Thus, genetic sequences can be patentable in India only when they are part of an invention with defined use, technical advantage, and industrial application — not merely as biological data or discoveries.
RELATED Blog
comments